Table 1.
Antibiotic characteristics of two P. aeruginosa isogenic isolates from the same patient.
| Antibiotic | PB367 | PB350 | ||
|---|---|---|---|---|
| MIC (mg/L) | Int | MIC (mg/L) | Int | |
| Amikacin | ≤ 16 | S | ≤ 16 | S |
| Aztreonam | > 16 | R | 16 | I |
| Ceftazidime | > 16 | R | > 16 | R |
| Ceftazidime/avibactam *, # | 4 | S | 64 | R |
| Ceftolozane/tazobactam * | 4 | S | 128 | R |
| Ciprofloxaxin | > 2 | R | > 2 | R |
| Cefepime | > 16 | R | > 16 | R |
| Gentamicin | > 8 | R | > 8 | R |
| Levofloxacin | > 4 | R | > 4 | R |
| Meropenem * | > 32 | R | 16 | R |
| Meropenem/vaborbactam *, # | 32 | R | 16 | R |
| Piperacillin/tazobactam | > 64 | R | 16 | S |
| Ticarcillin/clavulanate | > 64 | R | > 64 | R |
| Tobramycin | > 8 | R | > 8 | R |
MIC, minimum inhibitory concentration (mg/L); Int, interpretation; S, susceptible; I, intermediate; R, resistant; as per CLSI M100-S26 (2016). *, MIC was determined by E-test and #, interpretative criteria were based on FDA-approved drug package insert.